All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the EHA2021 Virtual Congress, the MDS Hub spoke with Vinod Pullarkat, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?
What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?
Pullarkat discusses the hematoloigc toxicities associated with venetoclax and azacitidine, which are largely related to cytopenias. He explains that the key to managing these toxicities is close monitoring of patients and providing transfusion support as needed. Finally, he mentions that a high percentage of patients will require dose modifications.
Subscribe to get the best content related to MDS delivered to your inbox